Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012; 19(7): 449–464
2. Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol 2010; 3(3): 191–202
3. US Food and Drug Administration. Approval of Victrelis (boceprevir) a direct acting antiviral drug (DAA) to treat hepatitis C virus (HCV). http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm255413 . Accessed 1 August 2013
4. US Food and Drug Administration. Approval of Incivek (telaprevir) a direct acting antiviral drug (DAA) to treat hepatitis C virus (HCV). http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm256328 . Accessed 1 August 2013
5. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1195–1206
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献